Mullen brings to Stonehill more than 25 years of international investment research, corporate finance and advisory, portfolio management and venture capital investment experience with a particular focus in life sciences and medical technology. A former partner of Wall Street-based Cowen & Co. and senior portfolio manager for the Bellevue Group of Zurich, Switzerland, he is currently Managing Director of Tarvos Capital Management, LLC. Through Tarvos Capital, Mullen maintains an exclusive investment research advisory relationship with Adamant Biomedical Investments AG, a majority owned subsidiary of Zürcher Kantonalbank, the third largest bank in Switzerland.
In addition to his accomplished work experience, Mullen has previously taught financial and managerial accounting at the undergraduate School of Business at Indiana University (IU) and has over the years, guest lectured at the IU MBA program among other colleges on topics such as equity research, portfolio management strategy, venture investing and entrepreneurship.
Mullen is a Chartered Financial Analyst, a Chartered Alternative Investment Analyst, a member of the Boston Society of Security of Analysts and member of the Board of Advisors of the IU MBA Investment Management Academy. Previous Board of Director experiences include Centelion S.A.S. (Sanofi), Eyetech Pharmaceuticals, Theravance, Auxilium and formerly founding Chairman of EyeGate Pharmaceuticals of Waltham, MA.
- M.B A., Indiana University
- B.S., Fordham University
- Chartered Financial Analyst
- Chartered Alternative Investment Analyst
- Applied Research & Portfolio Management
- Corporate Finance
- Entrepreneurial Finance
- Seminar in Financial Management